CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
Akhtar
M
M
Instituto di Clinica Medica II, Universitá di Milano, Italy.
Breithardt
G
G
Camm
A J
AJ
Coumel
P
P
Janse
M J
MJ
Lazzara
R
R
Myerburg
R J
RJ
Schwartz
P J
PJ
Waldo
A L
AL
Wellens
H J
HJ
D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004311:Double-Blind Method; D016700:Encainide; D005424:Flecainide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016293:Moricizine; D015337:Multicenter Studies as Topic; D010640:Phenothiazines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D016293:Moricizine; D005424:Flecainide; D016700:Encainide